Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

BACKGROUND: The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Med Genomics
Autors principals: Wallden, Brett, Storhoff, James, Nielsen, Torsten, Dowidar, Naeem, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Leung, Samuel, Geiss, Gary, Snider, Jacqueline, Vickery, Tammi, Davies, Sherri R., Mardis, Elaine R., Gnant, Michael, Sestak, Ivana, Ellis, Matthew J., Perou, Charles M., Bernard, Philip S., Parker, Joel S.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546262/
https://ncbi.nlm.nih.gov/pubmed/26297356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-015-0129-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars